Castle Biosciences Inc

Research Castle Biosciences Inc (CSTL) on Bullrun: market cap USD 1.07B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 1.07B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 344.23M-USD 24.16MUSD 28.33M79.4%-0.83USD 116.73MUSD 10.06MUSD 470.87M
FY2024USD 332.07MUSD 18.25MUSD 36.54M81.9%0.62USD 119.71MUSD 10.02MUSD 455.84M
FY2023USD 219.79M-USD 57.47M-USD 19.25M79.5%-2.14USD 98.84MUSD 0USD 391.27M
FY2022USD 137.04M-USD 67.14M-USD 47.29M76.6%-2.58USD 122.95MUSD 7.69MUSD 399.15M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 1.07Bn/an/an/a
20252025-12-31USD 1.15Bn/an/an/a
20242024-12-31USD 759.08M43.7n/an/a
20232023-12-29USD 580.73Mn/an/an/a
20222022-12-30USD 620.32Mn/an/an/a
20212021-12-31USD 1.09Bn/an/an/a

About Castle Biosciences Inc

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Castle Biosciences Inc's market cap?

Castle Biosciences Inc's market capitalization is USD 1.07B.

What does Castle Biosciences Inc do?

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.